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Recognition of <3 metastases in <2 organs, particularly in cancers with a known predisposition to oligometastatic disease
(OMD) (colorectal, prostate, renal, sarcoma and lung), offers the opportunity to focally treat the lesions identified and confers a
survival advantage. The reliability with which OMD is identified depends on the sensitivity of the imaging technique used for
detection and may be predicted from phenotypic and genetic factors of the primary tumour, which determine metastatic risk.
Whole-body or organ-specific imaging to identify oligometastases requires optimization to achieve maximal sensitivity.
Metastatic lesions at multiple locations may require a variety of imaging modalities for best visualisation because the optimal
image contrast is determined by tumour biology. Newer imaging techniques used for this purpose require validation.
Additionally, rationalisation of imaging strategies is needed, particularly with regard to timing of imaging and follow-up
studies. This article reviews the current evidence for the use of imaging for recognising OMD and proposes a risk-based
roadmap for identifying patients with true OMD, or at risk of metastatic disease likely to be OM.
Introduction
The development of metastases is driven by a variety of
tumour and host characteristics1,2 such as escape of tumour
cells from the primary site, their survival in the circulation
and lymphatics, seeding and invasion at a host metastatic site,
angiogenesis and immune escape.3,4 Where metastases are few
in number (<3 lesions in <2 organs), the term Oligometastatic
disease (OMD) has been coined.5 This lies between the situa-
tion of organ-confined localised disease and widespread
(poly-) metastases (PM) and carries a different prognostic
implication.6–8 Patients with OM may potentially be treated
with curative intent or attempt at long term disease or symp-
tom control, 9–11 which means that their management often
may differ from those with PM disease. Therefore, the identi-
fication of the true OM state on imaging is crucially impor-
tant. Particular tumour types are predisposed to an OM state;
these include colorectal, prostate, renal, sarcoma and lung
cancer. It is possible to potentially predict the probability of a
likely oligometastatic state from baseline tumour evaluation
that documents the primary tumour features on imaging (size,
volume, metabolism), histological typing and/or genetic profil-
ing as they reflect tumour burden and metastatic
propensity.12–15
The conditions that favour development of OM as opposed
to a PM have been modelled by Withers and Lee.16 They rec-
ognise 4 predisposing factors. Firstly, a long interval between
surgical removal of the primary and the appearance of a single
metastasis – late appearance of a metastasis implies a long
doubling time of a lesion that was undetectable at the time of
surgery and therefore either solitary lesion or with a limited
number of followers. Secondly, a single slow-growing meta-
static deposit with a large difference in volume between it and
any measurable followers indicates a greater probability of
OMD. Thirdly, a solitary metastasis in the presence of a large
primary tumour is also more likely to indicate an OM state
and fourthly effective chemotherapy that wipes out microme-
tastatic burden is more likely to predispose to an OM
recurrence.
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This article reviews the role of imaging in defining OMD.
It acknowledges the limitations of current imaging modalities,
which may be poorly sensitive, and the challenges of imple-
menting newer, more sensitive imaging modalities that largely
remain nonstandardised and invalidated, issues that have been
recently addressed comprehensively.17 Here we discuss the
optimal timing and frequency of follow-up with the relevant
imaging techniques in relation to tumour biology and specifi-
cally include evaluation of features of the primary tumour that
may be used to assess metastatic risk.
Metastatic Risk Assessment
Histological and genetic features of the primary tumour: can
OM and PM disease be predicted?
It has long been known that histological type and grade of a
tumour is indicative of metastatic risk.18,19 A breast cancer
series of >2,000 patients from 8 German centres showed that
metastases at presentation were more commonly associated
with grade 3 lobular histology and a Luminal B phenotype
(HER2 positive).20 In primary soft-tissue sarcoma, where his-
tological type varies widely, tumour grade has been shown to
be independent of histological subtype for predicting meta-
static relapse.21 In renal cell cancer, the Leibovich score
(clear cell subtype) and UICC/AJCC grading (other sub-
types) are used for risk stratification: high risk patients have
a ~60% risk of recurrence at 5 years versus 10% in low risk
disease. Often recurrences are solitary or oligometastatic
(41% of 68 patients in one retrospective study).22 However,
although histological grading identifies metastatic risk, there
is no data to indicate a preferential distinction between OM
or PM phenotypes.
Comparison of the genetic features of patients with OM
who subsequently turn out to be PM vs. those who were truly
OM has revealed interesting differences. Distinct microRNA
expression patterns were found in a small study of 34 patients,
all of whom had received radiotherapy with curative intent to
their oligometastases, these patterns were not just evident in
the oligometastasis, but also in the primary tumour itself.23 It
was possible in this pilot study to prioritise these microRNA’s
that differed between primary tumours known to develop OM
versus PM and use them to predict the OM state in metastatic
samples. The pathways targeted by these microRNA’s relate to
suppression of cellular adhesion, invasion and motility. In
particular, four microRNAs encoded in the 14q32 locus (miR-
127-5p, miR-369-3p, miR-544a, and miR-655-3p) were associ-
ated with an OM phenotype in clinical metastasis samples. In
vitro assays of adhesion and invasion using metastatic cell
lines transfected with these microRNA’s resulted in a signifi-
cant decrease in adhesion to Matrigel as compared to nontar-
geted control transfected cells. Further, ectopic expression of
selected 14q32-encoded miRs or stable repression of targeted
genes by shRNAs led to reversal of a PM phenotype to an
OM phenotype.24
Imaging the primary tumour to distinguish OM from PM
In addition to T-staging, the phenotype of a tumour on imag-
ing is a well-established predictor of disease progression/out-
come. In rectal cancer, pre-operative high resolution T2-W
MRI can distinguish prognostic groups based on assessment
of depth of extramural spread, relationship of the tumour
edge to the mesorectal fascia and extramural venous inva-
sion.25 Likewise, in synovial sarcoma, T1 stage, as well as het-
erogeneous enhancement, interfascial extension and
perilesional oedema indicate a higher incidence of metastatic
disease.26 Angiogenic capability of tumours is another imaging
feature associated with metastatic potential: inhibiting VEGF
in subcutaneous breast cancer models substantially reduced
the development of metastases.27 High expression of metasta-
sis associated protein (MTA1) in oral squamous cell carci-
noma has been associated with increased tumour angiogenesis
and progression to metastasis,28 while in papillary thyroid
cancer, angiogenesis as measured by immunohistochemistry
of microvessel density is more intense among metastatic
tumours.29 However, there are as yet no data indicating a dif-
ferential angiogenic capability of an OM versus a PM
phenotype.
Evidence also links functional imaging-based tumour prop-
erties to metastatic disease, prognosis and survival. In non-
small cell lung cancer (NSCLC), quantitative measures of PET
tracer uptake – (so called-Maximum Standardised Uptake
Value (SUVmax)) has been shown to be able to predict occult
nodal metastases from the metabolic activity of the primary
tumour.30 In a multivariate analysis SUVmax was independent
of tumour size and importantly type of tumour, for predicting
the presence of occult lymph node metastasis.31 In an initial
study of 63 patients, an Optimal cut-off value of 8.8 SUVmax
of the primary tumour was shown to predict occult metastases
in NSCLC32 although in another larger cohort (n = 163), an
SUVmax of 7 was deemed to be the best threshold for indicat-
ing metastatic risk; a value <7 was shown to be an indepen-
dent prognostic factor for metastasis-free survival.33 High
SUV as an independent biomarker of prognosis has been
borne out in lung cancer (meta-analysis of 21 lung cancer
studies had a combined hazard ratio of 2.08),34 in breast can-
cer (hazard ratio 2.39)35 and in soft-tissue sarcoma (hazard
ratio 3.75),36 where it has been related to mitotic count.37 In
renal cell cancer, the apparent diffusion coefficient (ADC)38
derived from diffusion-weighted MRI and SUVmax from
18FDG-PET have been shown to be statistically significant
independent risk factors for high histological grade and hence
of metastatic risk.39
Heterogeneity of morphological and functional imaging
features is proving of interest in predicting metastatic risk.
Although the data from 18FDG PET remains controversial40,41
entropy measures from histogram analyses of MRI based
tumour ADC can predict positive nodal status in rectal can-
cers42 and in gastric cancers, while in soft-tissue sarcomas,
first order statistics from ADC, which relate to signal
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variability and to entropy and dissimilarity, were higher in
high grade tumours.43
Finally, the initial response of the primary tumour to a
given chemotherapy is also a powerful prognostic
indicator44–47 for subsequent development of metastases. Data
from the International Metastatic Renal Cell Carcinoma
(mRCC) Database Consortium showed that solitary versus
multiple metastases were commoner in long-term survivors
(ratio 0.3 vs. 0.2) treated with targeted agents, mainly VEGF
and mTOR inhibitors.48 In soft-tissue sarcomas (n = 34); free-
dom from distant metastasis was superior if treatment-
induced tumour necrosis was 90% or greater (84.6%
vs. 19.9%, p = 0.02) indicating likely control of micrometas-
tases in these patients.49 In metastatic colorectal cancer, the
hazard ratio for progression-free survival among patients with
wild-type-KRAS tumours was 0.68 (95% CI, 0.50 to 0.94) in
favour of a cetuximab-FOLFIRI combination treatment com-
pared to a FOLFIRI alone group (n = 599 in each arm)50
emphasising the critical role of effective chemotherapy in con-
trolling distant disease. In 228 rectal cancer patients followed-
up for a median of 49 months, pathological response as
defined by tumour regression grade was the only independent
factor for predicting subsequent metastases,51 further
highlighting the vital role of effective chemotherapy in deter-
mining metastatic risk. As chemotherapy becomes more effec-
tive, it is expected that the likelihood of OM as opposed to
PM disease will increase.
Imaging for detecting OMD
Available modalities
The commonest sites of metastases (OM or PM) are liver,
lung, skeletal and nodal. While the first two require imaging
with dedicated organ coverage, imaging requirements for the
latter two necessitate whole-body techniques. Important con-
siderations are the selection of the imaging technique that
delivers maximal sensitivity and specificity for disease detec-
tion, appropriate organ coverage and the optimal timing and
intensity of imaging follow-up.
CT scans detect metastases within soft-tissues and bone
based on a change in tissue morphology and density. MRI can
also detect functional features such as tumour vascularity, cel-
lularity, stiffness and metabolism. Bone scintigraphy52–54
reflects bone remodelling and is not specific for metastatic
tumour itself, with sensitivity around 85% for the identifica-
tion of bone metastases on a patient level with a specificity of
75–80%. Glucose avidity on 18FDG-PET is directly related to
metabolic activity and turnover of tumour cells and is particu-
larly effective in recognising OM or monometastatic disease.55
Despite the sensitivity of, 18FDG PET-CT for metastasis detec-
tion in lung cancer, it is not routinely recommended for
follow-up56 although it is common practice in academic
centres.
If metastatic risk is more likely at a particular site, high-
resolution imaging should focus on the region-of -interest
(e.g. CT or MRI with liver-specific contrast agents in colo-
rectal disease, or high-resolution chest CT in sarcoma).
Conversely, full body coverage with MRI or PET needs to
be retained where skeletal or multiple organ involvement is
more likely (e.g. for prostate cancer). In addition to spatial
resolution, tumour to background contrast is vital for opti-
mal sensitivity of disease detection. A meta-analysis of nine
diagnostic accuracy studies (537 patients with 1,216 lesions)
and four change-in-management studies (488 patients with
281 lesions) emphasises the vital importance of tumour to
background contrast in lesion detection. The per-lesion
sensitivity and specificity for contrast-enhanced-MRI ran-
ged from 86.9–100.0% and 80.2–98.0%, respectively, com-
pared to 51.8–84.6% and 77.2–98.0% for contrast-
enhanced-CT because of the superior image contrast of the
former.57
Sensitivity and specificity of PET imaging for detecting
OM may be optimised further by disease-specific radiotracers
directed against tumour specific antigens. A pitfall of these
techniques lies in the differential expression of the antigens in
tumour versus normal tissue and in changing tumour biology.
For example, 18F-fluorodihydrotestorsterone (18F-FDHT) a
radio-labelled dihydrotestosterone analogue, directly targets
the androgen receptor (AR) on tumour cells. However, testos-
terone levels above castration level means that competitive
binding can hamper accurate FDHT evaluation. Similarly,
68Ga-labelled prostate-specific membrane antigen (PSMA)
used to image prostate cancer may be falsely negative in the
liver where a high background activity can potentially obscure
lesions, or when liver metastases tend to lose PSMA-
expression in advanced metastatic disease. Sensitivity, specific-
ity and accuracy against a surgical gold standard for lymph
node detection in a multicentre study for 68Ga-PSMA PET in
the primary setting were 53%, 86% and 76% but improved
with higher surgical sampling, increasing to 67%, 88% and
81% in a subgroup with of patients with ≥15 lymph nodes
removed.58 Imaging data for these newer agents has been vali-
dated and shown to reflect target expression: a small but
intensive study of targeted agents such as 18F-DHT and 18F-
ES (Estradiol) showed that semi-quantitative androgen or oes-
trogen receptor expression on immunohistochemistry and
18F-DHT or 18F-ES uptake respectively on PET was correlated.
Moreover, using optimal cut-offs (SUVmax of 1.94 for
18FDHT-PET and 1.54 for 18FES-PET) sensitivities of 91%
and 100% and specificities of 100% and 100% respectively
were achieved.59
Whole-body MRI has the advantage of combining mor-
phological data (T1 and T2-W imaging) with functional infor-
mation (diffusion-weighted and dynamic contrast-enhanced
imaging) thus simultaneously exploiting multiple contrast
mechanisms to image and detect the presence of disease. As
diffusion-weighted and contrast-enhanced MRI data are fun-
damentally quantitative, thresholding can be set so that the
images display the required sensitivity and specificity.
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Anatomic images are most useful at the early stages, i.e. at
presentation or first biochemical recurrence. At later stages of
disease, morphologic images can be more difficult to interpret,
especially with the appearance of new lesions or reactivation
of previously responding metastases on a background of trea-
ted lesions. Here the role of diffusion-weighted sequences
becomes crucial.60 Inverted greyscale images of maximum
intensity projections of high b-value images in conjunction
with the morphological images are helpful to detect metastatic
foci (Fig. 1).61 Qualitative assessment of inverse maximum
intensity projection of high b-value images 62 visually appear
like radioisotope studies and need comparison with morpho-
logical imaging for verification. Although highly sclerotic
metastases may be missed on high b-value DWI images, they
are correctly identified on anatomic MR images, which also
identifies any T2 shine through effect. Inter-observer agree-
ment for reading of WB-MRI images including DWI has been
evaluated as very good (K = 0.87 [Confidence Interval 0.66;
1.00]) in several studies62,63 outperforming a moderate inter-
observer agreement for bone scintigraphy (K = 0.60 [Confi-
dence Interval 0.26; 0.78])64 ADC maps provide information
on the cellularity, viability and changes over time and are
essential for lesion follow-up under treatment. Finally, apply-
ing an ADC threshold to the images enables automated
measurements of the global volume of metastatic disease,
which can be exploited as prognostic and response
biomarkers.65–67
Challenges in implementation
Despite the exponential availability of imaging and the
declining costs of genetic analyses needed to characterise
tumours, several challenges in effective recognition of OM
remain. Imaging detection sensitivity depends on the modali-
ties, spatial and contrast resolution. Spatial resolution
depends on hardware and software capabilities of the imag-
ing equipment (transducer frequency, detector arrays, mag-
netic field strength and gradients applied). With MRI, spatial
resolution is a trade-off against coverage, so can be as high
as 0.5mm3 for dedicated organ imaging but is around
50mm3 for whole body techniques. Generally, lesions <5 mm
are considered undetectable by RECIST (Response Evaluation
Criteria in Solid Tumours) criteria, as specificity is low for
small volume lesions. A 5 mm lesion effectively has a volume
of 65mm3 and therefore approximately 150–350 million cells
(based on a cell size of 200–400 microns,68 making this the
lower limit of detection of lesions with current standard
imaging techniques. The spatial resolution of PET imaging
techniques is dependent on the energy of the tracer and the
Figure 1. Eighty-one years. old male with oligometastatic prostate cancer: The patient presented 13 years previously with T3a, Gleason 4+4
prostate disease. He was treated with radiotherapy complemented by androgen blockade for 4 years. He experienced biochemical recurrence
10 years post diagnosis. Bone scintigraphy (a) showed a solitary metastasis in the lumbar spine (arrow), whole body MRI (b = 900 mm2/s)
confirmed this lesion (b, arrow) and revealed the additional rib lesion (c, open arrow), indicating the value of utilizing the most accurate
imaging modality at the outset prior to planning management.
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sensitivity of the detector arrays. For 18F, this is of the order
of 5-7 mm which means that generally lesions of <1 cm are
not reliably detected. Contrast resolution on the other hand,
depends not only on the imaging technique but may vary
with tumour biology. It is vitally dependent on differences in
properties between the tumour and the background tissue
(e.g. density for CT, tissue water relaxation after RF excita-
tion in a magnetic field in MR, uptake of extrinsic radio-
tracers on PET). Differences in cellular density and
extracellular matrix composition of metastases at different
anatomical locations may affect image contrast and pro-
foundly influence detection sensitivity. Poor image contrast
may mean that even a high spatial resolution technique such
as CT (30 microns) does not deliver the desired detection
sensitivity.
Radiotracer techniques that are target-specific are highly
sensitive (e.g. targeting somatostatin receptors has been widely
used for imaging neuroendocrine tumours)69 but may suffer
Table 1. Features of the primary tumour that aid distinguishing oligo- from poly-metastatic disease
Oligometastatic Polymetastatic
Histological Tumour grade in many cancer subtypes
(breast, renal, sarcoma) indicates
metastatic risk18–22 but has not been
shown to predict OM vs. PM
Genetic microRNA expression linked to OM phenotype23 Genetic heterogeneity of the primary
tumour is a risk for metastatic disease
in general
Morphology (Size,
shape)
Large, slow growing primary tumour16
Metastases small and uniform with
nonspecific shape or imaging features.
No distinguishing size or shape features-but
typically multi-focal and heterogeneous in
size and shape
Functional imaging
features
Angiogenic features, maximum standardised
uptake value on FDG-PET, apparent diffusion
coefficient on MRI are all
linked to tumour grade and metastatic risk,25–39
but no evidence for their
use in distinguishing OM from PM
Response to
chemotherapy
Good initial response to chemotherapy and
high tumour regression grade, indicate good
control of micrometastases and favour OM at
recurrence16
Poor or very mixed initial response to
chemotherapy favours PM at recurrence
Figure 2. Proposal for an imaging workflow for detection of oligometastatic disease. [Color figure can be viewed at wileyonlinelibrary.com]
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from specificity issues if the target is expressed more generally
(HER2).70 Of note, 68Ga-PSMA PET can be false negative in
up to 5% of patients with prostate cancer, due to absent or
low expression of PSMA on prostate cancer cells. It also has
been reported that in advanced metastatic castration-resistant
prostate cancer, metastases (mainly in the liver) can lose
PSMA-expression.71–73
Accurate detection of metastatic lymph nodes remains the
holy grail of oncological imaging. Identification of abnormally
enlarged lymph nodes is the domain of CT where the sensitiv-
ity of detection of enlarged nodes depends upon the size
threshold utilised. In RECIST 1.1, nodes with short
axis ≥ 10 mm but <15 mm are considered pathological,
although nontarget lesions. CT is unable to detect architec-
tural changes within normal-sized (<10 mm) lymph nodes,
which results in a low sensitivity (40%) as the majority of
metastases are microscopic. The average specificity however is
around 80% against a surgical gold standard because reactive
or inflammatory change within lymph nodes results in false
positives. Despite the high spatial resolution of CT, the poor
contrast resolution means that it performs less well than
MRI.64 18F-Choline PET also has been trialled in several stud-
ies for metastatic node detection: in 130 prostate cancer
patients at high-risk for extra-capsular disease who underwent
radical prostatectomy, with 912 lymph nodes sampled 18F-
Choline PET/CT showed a better performance than CT for
detecting nodal involvement, particularly for metastases
greater or equal than 5 mm in size (sensitivity 66%, specificity
96%).74 However, this low sensitivity means that it does not
merit routine use. RECIST 1.1 criteria75 on either CT or MRI
therefore remains the mainstay for identifying nodal
metastases.
Validation of OMD on imaging remains hugely problem-
atic. It is not feasible to biopsy multiple sites, particularly in
bone and brain. Confirmation of accuracy of new imaging
agents is highly dependent on what is known from preclinical
studies, or on longitudinal follow-up observational data. The
imaging community have produced an imaging biomarker
roadmap that addresses these issues, which is being widely
implemented.76
Table 2. Advantages and Limitations of commonly available imaging modalities for detecting and assessing metastatic disease and treatment
response
Advantages Limitations
Bone Scintigraphy • Widely available
• Low cost
• Easy to implement, especially if high
suspicion of bone metastases
• Poor sensitivity (50%)
• Radiation dose (~3-4 mSv)
• Response assessment is challenging
CT • Widely available
• Relatively low cost
• Soft tissue and bone delineation
• High contrast in lung
• Sensitivity limited by poor soft tissue
contrast within abdomen and pelvis
(liver, peritoneum)
• Radiation dose (~10-14 mSv)
• Relative lack of standardisation
• Requires Iodinated contrast material
with potential nephrotoxicity
Organ-specific MRI • High inherent soft tissue contrast,
especially with diffusion-weighted
imaging
• No ionising radiation
• Availability of organ-specific
contrast agents for liver imaging
• Poor sensitivity in lung due to susceptibility
effects and motion artefact
• Relative lack of standardisation
• High cost
• May require Gadolinium chelates with
associated potential toxicities
Whole-body MRI • Whole-body coverage
• Multiple tissue contrasts yield
high sensitivity
• No ionising radiation
• Specificity low
• Lack of validation studies
• Limited availability
• High cost,
• Long examination time (45 mins)
• May be poorly tolerated by patient
18FDG-PET • High sensitivity55
• Whole-body coverage
• Combined metabolic (FDG) and
morphological (CT) data
• Radiation dose (~14 mSv)
• High cost
• Limited availability
• Limited spatial resolution for
subcentimeter lesions
Receptor specific
radiotracers
(18F-DHT, 68GA-PSMA)
• High specificity58
• Whole body coverage
• Combined tumour receptor
specific and morphological (CT) data
• High cost
• Availability limited to tertiary
cancer centres
• Radiation dose
• Follow-up where receptor expression
is negative yields false negatives
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Timing and Mode of Imaging follow-up
The timing of longitudinal or follow-up imaging studies is an
important consideration. Conventionally, after the effective
treatment of the primary tumour, patients are often imaged
3-monthly for the first year, 6-monthly for the next 2 years
and then annually or as the clinical situation demands.
Although the rationale for this is geared to detecting recur-
rence at the primary site it does not in fact fulfil the need for
detecting OM where the likelihood of detecting disease in the
first year is low with increasing likelihood thereafter. True
OM amenable to curative treatment will remain undetectable
until they reach a 230 cell burden and are unlikely to be mani-
fest in the first year. Over a decade ago Singh et al. followed
369 patients with Stage T1-T3aN0-NXM0 prostate cancer for
10-years who were treated with external beam radiation with
curative intent to a mean dose of 65Gy. There was a better
overall survival in patients with <5 metastases than those with
more numerous lesions.77 The location of these metastases
was largely in the spine and pelvis and only 2 patients had
disease elsewhere (lung, liver, brain). Moreover, the mean
interval from the date of the initial diagnosis of prostate can-
cer to the time of diagnosis of bone metastases was 4.9 years
(range 0.7–10.5) in the group with <5 lesions, compared with
3.3 years (range 0.5–10.7) in the group with >5 lesions
(p = 0.02). Dominant patterns of metastasis to suggest a
multi-step hierarchical order of metastasis did not occur.
Therefore, a follow-up protocol for detection of OM in pros-
tate cancer would ideally be intense and increased around the
4 year mark and employ the most sensitive techniques that
covered the spine and pelvis, either with a targeted radioiso-
tope or whole-body scanning, increasingly done with MRI
(Fig. 2). In nonmetastatic NSCLC, systematic interrogation of
patients treated with definitive radiation (≥60Gy) showed that
there were different patterns of metastatic spread.78 This
means that a whole-body, rather than a sequential targeted
imaging approach for detection is warranted.
Summary
Recognition of the metastatic potential of a tumour is crucial
in determining patients’ management pathway. Metastatic
propensity is traditionally based on histologic types although
increasingly genetic profiling is being used to stratify patients
to various management options with surgery, radiotherapy
and chemotherapy/Immunotherapy as appropriate. The addi-
tion of an imaging phenotype into this paradigm can have a
major impact on treatment decisions. Thereafter, a tumour
target-specific protocol that is organ-specific or requires a
whole-body approach can be decided on, depending on the
tumour type and likely mode of spread. A regime of more fre-
quent follow-up between 2 and 4 years after completion of
treatment rather than early post-treatment is most likely to
favour earlier recognition of OMD. Achieving an appropriate
cost-effective surveillance program for imaging patients at risk
of OMD opens the door to new therapeutic strategies for these
patients with the potential for cure.
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